Molecular Partners Ag MOLN

Molecular Partners AG is a clinical-stage biotechnology company pioneering the design and development of DARPin therapeutics for medical challenges that other drug modalities cannot readily address. The company focuses on oncology through a pipeline of preclinical and clinical programs leveraging its proprietary DARPin platform to create differentiated therapeutics such as targeted radiopharmaceuticals and immune cell engagers. Molecular Partners AG has programs targeting various cancers including small cell lung cancer ovarian cancer cholangiocarcinoma and acute myeloid leukemia with product candidates like MP0712 MP0726 MP0317 and MP0533. The company combines its two decades of DARPin expertise with strategic collaborations to advance product candidates that aim to offer higher efficacy and fewer adverse events compared to current standards of care.

Molecular Partners AG generates revenue primarily through strategic collaboration agreements and licensing deals with biopharmaceutical partners. The company has entered into co-development agreements such as the one with Orano Med for up to ten 212Pb-based Radio-DARPin therapies and a development agreement with Eckert & Ziegler for targeted alpha radio-therapeutics including 225Ac. These partnerships involve shared development costs milestone payments and potential royalties on commercialized products. Additionally Molecular Partners AG may receive revenue from option exercises technology licensing and future product sales upon regulatory approval and commercialization of its DARPin product candidates. The company serves pharmaceutical and biotechnology companies seeking innovative therapeutic solutions in oncology and other therapeutic areas.

The company operates through the following segments:

• Research and Development: This segment encompasses the discovery design preclinical testing and clinical development of DARPin product candidates across oncology programs including Radio-DARPin therapies such as MP0712 targeting DLL3 and MP0726 targeting MSLN immune cell engagers such as MP0317 targeting FAP x CD40 and MP0533 a tetra-specific T cell engager for AML and Switch-DARPin candidates such as MP0621 for hematopoietic stem cell transplantation. Activities include library screening protein engineering half-life extension surface modification and mechanistic studies to optimize therapeutic candidates.

• Strategic Partnerships and Collaborations: This segment involves managing alliances with external partners such as Orano Med and Eckert & Ziegler to co-develop and advance DARPin-based therapeutics. Activities include negotiating agreement terms coordinating preclinical and clinical work sharing intellectual property and aligning development strategies to leverage partner capabilities in areas such as targeted alpha therapy manufacturing and global commercialization.

• Intellectual Property Management: This segment focuses on protecting the company’s DARPin platform and product candidates through patent filings trade secrets and proprietary protection. Activities include prosecuting patent applications maintaining granted patents monitoring infringement risks and leveraging IP to support collaborations and fundraising efforts as of December 31 2025 the company held over 30 granted patents and over 90 pending applications across more than 25 patent families.

Molecular Partners AG operates in the highly competitive biotechnology industry specifically within the oncology and targeted therapeutic modalities space. The company differentiates itself through its proprietary DARPin platform which offers advantages such as high affinity and specificity small size multispecificity tunable half-life and high-yield microbial manufacturing. These properties enable precise tumor targeting and reduced off-target effects compared to conventional antibodies and small molecules. While facing competition from larger pharmaceutical companies with greater resources Molecular Partners AG leverages its two decades of DARPin experience intellectual property portfolio and strategic collaborations to position itself as an innovator in next-generation radiopharmaceuticals and immune cell engagers.

Molecular Partners AG serves pharmaceutical and biotechnology companies academic institutions and research organizations through its collaboration and licensing activities. Specific partners mentioned in the filing include Orano Med for co-development of Radio-DARPin therapies and Eckert & Ziegler for targeted alpha radio-therapeutics. The company also engages with research institutions such as the University of Freiburg and the Paul Scherrer Institute for joint research initiatives. Its DARPin product candidates are ultimately intended to treat patients with serious diseases particularly cancer indicating that the end-user customer base includes hospitals oncology clinics and patients undergoing treatment for conditions such as small cell lung cancer ovarian cancer cholangiocarcinoma and acute myeloid leukemia.